T1	Participants 64 125	hospitalized patients with lower respiratory tract infections
T2	Participants 272 327	121 patients was studied; 92 were clinically evaluable.
T3	Participants 338 377	59 patients were treated with ofloxacin
T4	Participants 382 410	33 with the comparator drug.